JP2008512491A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512491A5
JP2008512491A5 JP2007531416A JP2007531416A JP2008512491A5 JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5 JP 2007531416 A JP2007531416 A JP 2007531416A JP 2007531416 A JP2007531416 A JP 2007531416A JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5
Authority
JP
Japan
Prior art keywords
composition
tumor cell
cell population
cells
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007531416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512491A (ja
Filing date
Publication date
Priority claimed from US10/937,658 external-priority patent/US20060057127A1/en
Application filed filed Critical
Publication of JP2008512491A publication Critical patent/JP2008512491A/ja
Publication of JP2008512491A5 publication Critical patent/JP2008512491A5/ja
Withdrawn legal-status Critical Current

Links

JP2007531416A 2004-09-10 2005-09-09 前立腺癌の処置のためのサイトカイン発現細胞ワクチン Withdrawn JP2008512491A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/937,658 US20060057127A1 (en) 2004-09-10 2004-09-10 Cytokine-expressing cellular vaccines for treatment of prostate cancer
PCT/US2005/032357 WO2006031703A1 (en) 2004-09-10 2005-09-09 Cytokine-expressing cellular vaccines for treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2008512491A JP2008512491A (ja) 2008-04-24
JP2008512491A5 true JP2008512491A5 (enExample) 2008-10-02

Family

ID=36034247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531416A Withdrawn JP2008512491A (ja) 2004-09-10 2005-09-09 前立腺癌の処置のためのサイトカイン発現細胞ワクチン

Country Status (6)

Country Link
US (1) US20060057127A1 (enExample)
EP (1) EP1789082A4 (enExample)
JP (1) JP2008512491A (enExample)
CN (1) CN101076351A (enExample)
CA (1) CA2577989A1 (enExample)
WO (1) WO2006031703A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
WO2008013989A2 (en) 2006-07-27 2008-01-31 Cell Genesys, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
US8378084B2 (en) * 2006-12-22 2013-02-19 The Regents Of The University Of California Fusion molecule based on novel TAA variant
JP5247729B2 (ja) * 2007-03-02 2013-07-24 セルル ゲネスイス,インコーポレイテッド 前立腺癌、又は前立腺癌に対する体液性免疫応答を同定するための方法、及び組成物
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
KR20150023904A (ko) 2012-06-27 2015-03-05 버그 엘엘씨 전립선암의 진단 및 치료에서의 마커의 용도
CA2933722C (en) 2014-01-14 2019-03-12 The Procter & Gamble Company A multi-step product for improving the appearance and feel of human skin
US9446265B2 (en) 2014-01-14 2016-09-20 The Procter & Gamble Company Cosmetic composition
WO2015108947A1 (en) 2014-01-14 2015-07-23 The Procter & Gamble Company A multi-step product for improving the appearance and feel of human skin
US10206859B2 (en) 2014-07-29 2019-02-19 The Procter & Gamble Company Cosmetic composition
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
DE69824859T2 (de) * 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
AU741602B2 (en) * 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification

Similar Documents

Publication Publication Date Title
Wang et al. Oxygen‐deficient molybdenum oxide nanosensitizers for ultrasound‐enhanced cancer metalloimmunotherapy
JP2008512491A5 (enExample)
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
EP2172212A3 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
JP2010516259A5 (enExample)
JP2011525191A5 (enExample)
CA2354046A1 (en) New cancer treatments
MX2008007286A (es) Ingenieria in vivo de superficie celular.
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
EP3238782A3 (en) Methods of treating cancer
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
IL191627A (en) Beta glycolipids as immuno-modulators
IL180612A0 (en) Materials and methods for immune system stimulation
WO2003061591A3 (en) Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
EP2385060A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
Qin et al. Unveiling the Multiple Tumor‐Targeted Impairments of Covalent‐Organic Framework‐Switched Photothermal Shielding Nanoparticles
WO2010045573A3 (en) Tumor vaccine
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
JP2018522880A5 (enExample)
SI1530628T1 (sl) Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
WO2009032256A3 (en) Apc activators in combination with a cytokine-secreting cell and methods of use thereof